SGYP - Synergy Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.0800
-0.0502 (-38.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.1302
Open0.1100
Bid0.09 x 1000
Ask0.09 x 1400
Day's Range0.0765 - 0.1182
52 Week Range0.0765 - 2.8000
Volume47,440,218
Avg. Volume6,933,439
Market Cap19.843M
Beta (3Y Monthly)3.38
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • The Wall Street Journal16 hours ago

    [$$] Synergy Pharmaceuticals Moves Forward on Path Toward Sale

    During a hearing Thursday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. expressed concern about moving too quickly but authorized the company to continue to pay employees, access bank accounts and maintain other routine operations. Inc., formerly known as Valeant Pharmaceuticals International Inc., for around $200 million in cash.

  • Zacks2 days ago

    Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals

    Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / Shares of both Neurocrine Biosciences and Synergy Pharmaceuticals were in the red on Wednesday after announcing discouraging developments. Synergy is selling its business assets while Neurocrine Biosciences failed to meet a primary goal in a mid-stage trial. Neurocrine Biosciences, Inc. shares were down almost 14% on about 13 million shares traded yesterday.

  • The Wall Street Journal2 days ago

    [$$] Bausch Health Agrees to Buy Synergy Pharmaceuticals for $200 Million

    Synergy Pharmaceuticals Inc. filed for bankruptcy Wednesday with a plan to sell its assets to Bausch Health Companies Inc. for around $200 million in cash. The deal includes all rights to Synergy’s flagship product Trulance, a tablet approved for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation, as well as another development-stage compound and related intellectual property. “We have worked diligently to serve our patients, health care professionals and other stakeholders by bringing Trulance to market and developing other [gastrointestinal] therapies to address previously unmet needs,” said Synergy Chief Executive Troy Hamilton.

  • InvestorPlace3 days ago

    Synergy Pharmaceuticals Bankruptcy: SGYP Stock Plummets on Filing

    Synergy Pharmaceuticals (NASDAQ:SGYP) has filed for Chapter 11 bankruptcy in a voluntary petition with another pharmaceutical company absorbing most of the company’s assets once the move goes through. The bankruptcy filing will be followed by Bausch Health (NYSE:BHC) taking over as a “stalking horse” bidder for the company in an auction and sale process that has been approved by a court. The acquisition of Synergy’s assets will be part of a deal valued at roughly $200 million that is slated to be complete at the end of the first quarter of 2019.

  • No Emoji Could Hide This Drugmaker’s Woes
    Bloomberg3 days ago

    No Emoji Could Hide This Drugmaker’s Woes

    The problem doesn’t appear to have been the stigma around talking about bowel movements — an issue Synergy hoped to address with those (animated!) emojis — but rather a highly competitive market.(2)Trulance has made little headway against better established drugs like Allergan PLC’s Linzess and Takeda Pharmaceutical Co.’s Amitiza.

  • The Wall Street Journal3 days ago

    [$$] Former Pharma Highflier Appreciates Bathroom Humor

    , formerly known as Valeant Pharmaceuticals, is back in the acquisitions game after a long hiatus. The deal gives Bausch access to Synergy’s lead drug Trulance, which treats irritable bowel syndrome. The deal is Bausch’s first major acquisition since 2015.

  • MarketWatch3 days ago

    UPDATE: Synergy Pharma shares slide 55% as it files for Chapter 11, clearing way for sale too Bausch

    Synergy Pharmaceuticals Inc. shares slid 55% in premarket trade Wednesday, after the company filed a voluntary petition for Chapter 11, allowing Bausch Health Cos. Inc. to serve as "stalking horse" bidder for the company in a court-approved auction and sale processes. Bausch, the former Valeant, will acquire Synergy's assets in a deal valued at about $200 million that is expected to close in the first quarter of 2019. Synergy specializes in gastrointestinal therapies, including its flagship Trulance product, a once-a-day table approved for adults with chronic constapion and irritable bowel syndrome with constipation. That product will complement Bausch's Salix business, Chief Executive Joseph Papa said in a statement. Bausch shares were up slightly premarket, and have gained 11% in 2018, while the S&P 500 has fallen 1.4%.

  • PR Newswire3 days ago

    Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.

    LAVAL, Quebec, Dec. 12, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in a transaction valued at approximately $200 million plus certain assumed liabilities. Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the "Bankruptcy Code") with the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") earlier today. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health will serve as the "stalking horse" bidder in a court-supervised auction and sale process, which Synergy will conduct pursuant to Section 363 of the Bankruptcy Code.

  • PR Newswire3 days ago

    Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets

    NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced an agreement with Bausch Health Companies Inc., through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE® (plecanatide), dolcanatide and related intellectual property, for approximately $200 million in cash, subject to certain adjustments at closing, plus the assumption of certain liabilities related to the assets to be acquired. The sale is subject to a competitive process and the Company's receipt of higher and better offers.

  • See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

    Synergy Pharmaceuticals Inc NASDAQ/NGS:SGYP

  • See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

    Synergy Pharmaceuticals Inc NASDAQ/NGS:SGYP

  • GlobeNewswirelast month

    Recent Analysis Shows Brown Forman, CryoLife, Aspen Group, Taylor Devices, Synergy Pharmaceuticals, and Ramco-Gershenson Properties Trust Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Synergy Pharmaceuticals (SGYP) Reports Q3 Loss, Misses Revenue Estimates
    Zackslast month

    Synergy Pharmaceuticals (SGYP) Reports Q3 Loss, Misses Revenue Estimates

    Synergy Pharma (SGYP) delivered earnings and revenue surprises of -7.69% and -29.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Synergy Pharma: 3Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 14 cents. The biopharmaceutical company posted revenue of $11.1 million in the period. In the final minutes of trading on Thursday, ...

  • Business Wirelast month

    Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update

    Synergy Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, today reported its financial results and business update for the three months ended September 30, 2018.

  • Motley Foollast month

    What We Can Learn From Synergy Pharmaceuticals' Disastrous News

    The revelation that this biotech may be on borrowed time is a great reminder to investors to analyze balance sheets.

  • Motley Foollast month

    Scary Markets, Frightening Stocks, and How to Keep From Panicking

    Here's what you need to know to keep your cool in terrifying times.

  • Business Wirelast month

    Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman

    Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independent Director of Synergy since August 2008, will now assume the role of Chairman of the Board, effective immediately. Synergy’s outgoing Executive Chairman, Gary S. Jacob, Ph.D., will leave the Company to pursue other opportunities. Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

  • Why Synergy Pharmaceuticals, Tesla, Tencent and More Are Trending
    Insider Monkey2 months ago

    Why Synergy Pharmaceuticals, Tesla, Tencent and More Are Trending

    The markets are in the red again on Friday as all three major indexes are down by over 1%. Among the stocks trending include Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Tesla Inc (NASDAQ:TSLA),Tencent Holdings Ltd (OTCMKTS:TCTZF),Flex Ltd (NASDAQ:FLEX), Lantronix Inc (NASDAQ:LTRX). Let’s take a closer look at why investors have been watching or selling those stocks. For those of you interested in […]

  • The Wall Street Journal2 months ago

    [$$] Investors Frown on Biotech Famed for Emojis

    shareholders have quite a mess on their hands. “To date, the offers received to acquire Synergy have been significantly below the company’s current market value, and it has been unable to consummate any partnerships,” the company said in a statement.

  • Why Synergy Pharmaceuticals Is Being Obliterated Today
    Motley Fool2 months ago

    Why Synergy Pharmaceuticals Is Being Obliterated Today

    Shares collapse after management provides investors with a series of troubling business updates. Here's the must-know information for shareholders.

  • Business Wire2 months ago

    Synergy Pharmaceuticals Provides Business Update

    Synergy Pharmaceuticals Inc. (SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today provided a business update. In April 2015, prior to the FDA approval and launch of TRULANCE® (plecanatide) in 2017, Synergy hired a top tier advisory firm to engage external parties and evaluate all strategic options available to the Company, including US and ex-US partnerships and a possible sale of the Company. Ultimately, there were no offers to acquire the Company and no partnership opportunities emerged in this evaluation that it believed aligned with the Company strategically or financially.

  • Business Wire2 months ago

    Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting

    Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the company will present new analyses that further reinforce the efficacy and safety of TRULANCE® (plecanatide) for adult patients with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), specifically in patients aged 65 and older and in patients using concomitant acid suppression medications such as proton pump inhibitors (PPIs) and/or histamine receptor antagonists (H2 blockers).

  • Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?

    Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.